ArticleInternational journal of surgery (London, England)2026
Insights into the mechanisms of drug resistance in renal cell carcinoma: from multi-omics perspective.
Article in International journal of surgery (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cytotoxicity Evaluation of Chalcones and Flavanones from the Leaves ofBiomolecules · 2026Article
- RNA-binding protein RBM47 in health and disease: molecular mechanisms, preclinical evidence, and translational challenges.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal cell carcinoma (RCC) is a prevalent malignancy of the urinary system. Despite significant advances achieved through targeted therapies and immunotherapies, therapeutic resistance remains a major obstacle to sustained clinical efficacy. This review comprehensively examines the molecular mechanisms driving resistance to both targeted therapy and immunotherapy in RCC from a multi-omics perspective. By integrating findings across diverse omics layers, we underscore the pivotal role of multi-level regulatory networks in mediating drug resistance and immune evasion. Our objective is to provide an in-depth understanding of these resistance mechanisms and to establish a theoretical framework for developing innovative therapeutic strategies aimed at overcoming resistance, thereby facilitating the advancement of precision oncology in RCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.